Neferine inhibits angiotensin II‑induced rat aortic smooth muscle cell proliferation predominantly by downregulating fractalkine gene expression

Zheng,Lulu; Cao,Yongwen; Liu,Shao; Peng,Zhenyu; Zhang,Saidan

doi:10.3892/etm.2014.1952

Neferine inhibits angiotensin II‑induced rat aortic smooth muscle cell proliferation predominantly by downregulating fractalkine gene expression

Authors:
- Lulu Zheng
- Yongwen Cao
- Shao Liu
- Zhenyu Peng
- Saidan Zhang
View Affiliations

Affiliations: Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Emergency, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: September 9, 2014 https://doi.org/10.3892/etm.2014.1952
Pages: 1545-1550

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neferine inhibits the angiotensin II (AngII)‑induced proliferation of vascular smooth muscle cells (SMCs), but the underlying mechanism is unclear. The aim of this study was to explore the mechanism underlying the effect of neferine on the proliferation of vascular SMCs. Rat aortic SMCs (RASMCs) were used and fractalkine (Fkn) gene expression was measured by quantitative polymerase chain reaction and western blot analysis. The proliferation of RASMCs was analyzed by MTT assay and flow cytometry. It was revealed that AngII induced Fkn expression in a dose‑ and time‑dependent manner. Fkn‑knockdown with small interfering RNA attenuated the AngII‑induced RASMC proliferation. Furthermore, neferine inhibited Fkn expression and attenuated the AngII‑induced RASMC proliferation. These findings suggest that the Fkn gene may play an important role in AngII‑induced RASMC proliferation and that neferine acts to attenuate AngII‑induced RASMC proliferation by inhibiting Fkn expression.

View Figures

View References

1	Viiri LE, Full LE, Navin TJ, Bequm S, Didangelos A, Astola N, Berge RK, Seppälä I, Shalhoub J, Frankin IJ, Perretti M, Lehtimäki T, Davies AH, Wait R and Monaco C: Smooth muscle cells in human atherosclerosis: proteomic profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease. J Mol Cell Cardiol. 54:65–72. 2013. View Article : Google Scholar
2	Savoia C, Burger D, Nishigaki N, Montezano A and Touyz RM: Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med. 13:e112011. View Article : Google Scholar : PubMed/NCBI
3	Liu G, Hitomi H, Hosomi N, Lei B, Pelisch N, Nakano D, Kiyomoto H, Ma H and Nishiyama A: Mechanical stretch potentiates angiotensin II-induced proliferation in spontaneously hypertensive rat vascular smooth muscle cells. Hypertens Res. 33:1250–1257. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kasal DA and Schiffrin EL: Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Int J Hypertens. 2012:8297862012.PubMed/NCBI
5	Touyz RM and Schiffrin EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 52:639–672. 2000.PubMed/NCBI
6	Eguchi S, Dempsey PJ, Frank GD, Motley ED and Inagami T: Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem. 276:7957–7962. 2001. View Article : Google Scholar : PubMed/NCBI
7	Shi R, Hu C, Yuan Q, Yang T, Peng J, Li Y, Bai Y, Cao Z, Cheng G and Zhang G: Involvement of vascular peroxidase 1 in angiotensin II-induced vascular smooth muscle cell proliferation. Cardiovasc Res. 91:27–36. 2011. View Article : Google Scholar : PubMed/NCBI
8	Zhao Y, Liu J, Li L, Liu L and Wu L: Role of Ras/PKCzeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept. 128:43–50. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature. 385:640–644. 1997. View Article : Google Scholar : PubMed/NCBI
10	Balabanian K, Foussat A, Dorfmüller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, Simonneau G, Emilie D and Humbert M: CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med. 165:1419–1425. 2002. View Article : Google Scholar : PubMed/NCBI
11	Schäfer A, Schulz C, Fraccarollo D, Tas P, Leutke M, Eigenthaler M, Seidl S, Heider P, Ertl G, Massberg S and Bauersachs J: The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol. 27:55–62. 2007.PubMed/NCBI
12	Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, Bin J and Kitakaze M: Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res. 92:385–393. 2011. View Article : Google Scholar : PubMed/NCBI
13	Sullivan JC, Pardieck JL, Doran D, Zhang Y, She JX and Pollock JS: Greater fractalkine expression in mesenteric arteries of female spontaneously hypertensive rats compared with males. Am J Physiol Heart Circ Physiol. 296:H1080–H1088. 2009. View Article : Google Scholar : PubMed/NCBI
14	Perros F, Dorfmüller P, Souza R, Durand-Gasselin I, Godot V, Capel F, Adnot S, Eddahibi S, Mazmanian M, Fadel E, Hervé P, Simonneau G, Emilie D and Humbert M: Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J. 29:937–943. 2007. View Article : Google Scholar : PubMed/NCBI
15	Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F and Melby PC: Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J. 373:547–558. 2003. View Article : Google Scholar
16	Rius C, Piqueras L, González-Navarro H, Albertos F, Company C, López-Ginés C, Ludwig A, Blanes JI, Morcillo EJ and Sanz MJ: Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiorensin-II. Arterioscler Thromb Vasc Biol. 33:96–104. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhao L, Wang X, Chang Q, Xu J, Huang Y, Guo Q, Zhang S, Wang W, Chen X and Wang J: Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmcol. 627:304–312. 2010. View Article : Google Scholar : PubMed/NCBI
18	Pan Y, Cai B, Wang K, Wang S, Zhou S, Yu X, Xu B and Chen L: Neferine enhances insulin sensitivity in insulin resistant rats. J Ethnopharmacol. 124:98–102. 2009. View Article : Google Scholar : PubMed/NCBI
19	Lalitha G, Poornima P, Archanah A and Padma VV: Protective effect of neferine against isoproterenol-induced cardiac toxicity. Cardiovasc Toxicol. 13:168–179. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ho HH, Hsu LS, Chan KC, Chen HM, Wu CH and Wang CJ: Extract from the leaf of nucifera reduced the development of atherosclerosis via inhibition of vascular smooth muscle cell proliferation and migration. Food Chem Toxicol. 48:159–168. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li XC, Tong GX, Zhang Y, Liu SX, Jin QH, Chen HH and Chen P: Neferine inhibits angiotensin II-stimulated proliferation in vascular smooth muscle cells through heme oxygenase-1. Acta Pharmacol Sin. 31:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
22	Liu S, Wang B, Li XZ, Qi LF and Liang YZ: Preparative separation and purification of liensinine, isoliensinine and neferine from seed embryo of Nelumbo nucifera GAERTN using high-speed counter-current chromatography. J Sep Sci. 32:2476–2481. 2009. View Article : Google Scholar : PubMed/NCBI
23	Ludwig A, Berkhout T, Moores K, Groot P and Chapman G: Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol. 168:604–612. 2002. View Article : Google Scholar : PubMed/NCBI
24	Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM and Greaves DR: Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation. 108:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
25	Ikejima H, Imanishi T, Tsujioka H, Kashiwagi M, Kuroi A, Tanimoto T, Kitabata H, Ishibashi K, Komukai K, Takeshita T and Akasaka T: Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J. 74:337–345. 2010. View Article : Google Scholar : PubMed/NCBI
26	Flierl U and Schäfer A: Fractalkine - a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost. 108:457–463. 2012. View Article : Google Scholar : PubMed/NCBI
27	Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ and Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 91:521–530. 1997. View Article : Google Scholar : PubMed/NCBI
28	Damås JK, Boullier A, Waehre T, Smith C, Sandberg WJ, et al: Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol. 25:2567–2572. 2005.PubMed/NCBI
29	Stolla M, Pelisek J, von Brühl ML, Schäfer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, Bray PF, Massberg S and Schulz C: Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One. 7:e435722012. View Article : Google Scholar : PubMed/NCBI
30	Combadière C, Potteaux S, Gao JL, Esposito B, Casanova S, et al: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 107:1009–1016. 2003.PubMed/NCBI
31	Lesnik P, Haskell CA and Charo IF: Decreased atherosclerosis in CX3CR1−/− mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 111:333–340. 2003.
32	Cheng JF, Ni GH, Chen MF, Li YJ, Wang YJ, Wang CL, Yuan Q, Shi RZ, Hu CP and Yang TL: Involvement of profilin-1 in angiotensin II-induced vascular smooth muscle cell proliferation. Vascul Pharmacol. 55:34–41. 2011. View Article : Google Scholar : PubMed/NCBI